BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Drug Development

  PharmaMar Presents Positive Results From a Phase II Study of lurbinectedin in Ewing’s Sarcoma at the CTOS International Congress

  PharmaMar has presented positive results from a Phase II study of lurbinectedin in Ewing’s sarcoma at the CTOS’s International Congress that took place in Hawaii from the 8th to the 11th of November.

  November 13, 2017

   · 

  1 min read
• BioMidwest

  Boehringer Ingelheim Release: Jardiance Reduced Risk of Cardiovascular Death in Adults With Type 2 Diabetes and Peripheral Artery Disease

  hese results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME trial, were shared as an oral presentation on behalf of Boehringer Ingelheim and Eli Lilly at the AHA Scientific Sessions 2017 in Anaheim, Calif. and simultaneously published online in the AHA’s journal, Circulation.

  November 13, 2017

   · 

  13 min read
• Drug Development

  Boehringer Ingelheim’s New RE-VERSE AD Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind) in Pradaxa Patients With GI Bleeding or Needing Emergency Surgery

  The analyses provide further insights on the use of idarucizumab in patients with GI bleeding and in those with a need for urgent surgery or intervention.

  November 13, 2017

   · 

  13 min read